Institutional Research Archive

Hedge Fund Letters Archive

Browse the world's most comprehensive database of hedge fund investor letters, sorted by recent quarter. Access primary source research from leading institutional managers.

Quarter	Letter Date	Fund Name	QTD	YTD	Tickers	Themes	Quick Take

Home Letters Funds Account

Conestoga Micro Cap Composite 2026 Q3 Investor Letter | Buyside Digest

Back to Fund Profile (Conestoga Micro Cap Composite)

Primary Source Intelligence • Q3 2026 Letter Analysis

Conestoga Micro Cap Composite Quarterly Analysis

Buyside Digest is not affiliated with, and does not endorse, Conestoga Micro Cap Composite. This analysis is provided for institutional research purposes only and is not investment advice.

Fund Returns

QTD-0.83%

YTD+12.5%

Annualized+10.58%

Positioning StanceCONSTRUCTIVE

Market CapMicroCap

GeographyUS

Digest Analysis

Quick Take

"Positioned defensively in high-quality, profitable micro-cap compounders across healthcare and enterprise technology, Conestoga initiated new long positions in Standex International and EZCORP while divesting lower-margin and higher-leverage businesses."

Executive Summary

The Conestoga Micro Cap Composite delivered strong relative capital preservation during the third quarter of 2026, declining -0.83% net of fees compared to a -12.15% drop for the benchmark Russell Microcap Growth Index, generating over 1,100 basis points of outperformance. Year-to-date through September 30, 2026, the strategy generated a net return of +12.50% net of fees, outpacing the benchmark return of +8.50%. The strategy maintained a concentrated portfolio of quality micro-cap growth equities, ending the period with a cash weighting of 3.4% and total composite assets of $56.2 million across 4 member portfolios within the firm's $3.8 billion institutional asset base. The broader market backdrop was heavily dictated by macroeconomic volatility, characterized by stubborn inflation prints, resilient labor conditions, and a 25 basis point rate hike by the Federal Reserve in September that lifted the federal funds rate to 3.75%-4.00%. Long-duration benchmark assets faced aggressive valuation compression, exacerbated by geopolitical friction in the Middle East that pushed crude oil prices above $100 per barrel. Despite these headwinds, the portfolio benefited from disciplined stock selection across secular growth niches, which shielded capital against factor rotations away from low-quality, unprofitable speculative equities. Relative outperformance was anchored by strong operational gains in Health Care, Technology, and Financials. Core contributors included bioprocessing and synthetic biology providers Twist Bioscience and BioLife Solutions, alongside enterprise software businesses. The strategy actively deployed capital by initiating new positions in Standex International and EZCORP, while exiting Hillman Solutions due to slowing organic growth and rising balance sheet leverage, and harvesting Bowman Consulting Group following an announced take-private acquisition.

Unlock Full Institutional Analysis

Sign in or create a free account to unlock full commentary, extracted equity pitches, and direct outbound manager source links with your 3 quarterly credits.

Sign In to Unlock (3 Free Credits)View Pricing Tiers

Institutional Meta Strategy

Meta Strategy Gauges

Algorithmic conviction, macroeconomic posture, and risk appetite signals extracted from this quarterly letter with qualitative explanations.

Signal Matrix

Market Conviction

72%

CautiousHigh

High Conviction (72%)

Conestoga demonstrates concentrated conviction by allocating 42.67% of the Micro Cap Composite to its top ten equity holdings, including high-weight allocations in TWST, BLFS, and TKNO. The manager displayed decisive portfolio management by fully eliminating lower-quality holdings like HLMN when leverage elevated, though broad portfolio diversification across 4 accounts and ongoing macroeconomic monitoring moderately temper the score.

Growth Outlook

65%

BearishBullish

Bullish (65%)

The manager expresses constructive optimism that a transition to a mid-cycle economy will favor disciplined, high-quality small and micro-cap businesses. While acknowledging persistent inflation and elevated yields, Conestoga highlights historically attractive relative valuations and sound fundamental growth as supporting an optimistic multi-year outlook.

Risk Appetite

68%

DefensiveAggressive

Balanced (68%)

Portfolio positioning remains net long with only 3.4% held in cash, reflecting an active willingness to deploy capital into quality growth businesses. However, risk appetite is tempered by intentional underweights to highly cyclical, leveraged, and unprofitable biotechnology segments.

Capital Deployment

60%

De-riskingDeploying

Net Neutral (60%)

Deployment was net neutral to moderately constructive, with cash steady at 3.4% alongside 16 additions versus 7 trims, paired with the initiation of two new equity positions funded by take-private proceeds and targeted exits.

Forward Guidance

70%

CautiousExpansionary

Expansionary (70%)

The investment team exhibited an active deployment bias in 3Q26, executing sixteen position additions and opening new stakes in SXI and EZPW. Guidance points to continued selective additions in durable, profitable compounders that have undergone valuation compression.

Language Signal

64%

BearishBullish

Balanced (64%)

The commentary balances constructive discussions of strong order backlogs, record revenues, and attractive entry valuations against frequent mentions of inflation, rising Treasury yields, and multiple compression.

Perceived Risk

68%

Low RiskElevated

Elevated Risk (68%)

The letter details substantial macro risks including 25-year highs in long-term Treasury yields, sticky inflation, higher energy costs driven by conflict around the Strait of Hormuz, and potential AI spending fatigue.

Opportunity Density

70%

ScarceAbundant

Abundant (70%)

Conestoga highlights a rich opportunity set across micro-cap growth equities following widespread multiple compression, noting that underlying operational execution remains robust across enterprise software, healthcare tools, and specialized manufacturing.

Time Horizon

80%

Short-TermLong-Term

Decade+ (80%)

The manager emphasizes full-cycle compounding across a multi-year horizon, deliberately looking past temporary quarterly earnings noise in holdings like UTI, ELVA, and MAMA while maintaining low portfolio turnover.